Alumis Inc. - Common Stock (ALMS) — AI analysis & news
Alumis Inc. - Common Stock (ALMS) stock: 2 recent news items, neutral aggregate sentiment, AI analysis and market context on BestAIBroker.
Current sentiment read
Across the last 2 indexed ALMS stories, aggregate finance-aware sentiment is neutral (+0.00 on a -1 to +1 scale).
Why ALMS moved
Last significant move: -56.58% (negative).
ALMS experienced a sharp 56.6% decline primarily due to its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) failing to meet primary and key secondary endpoints. Although a high-interferon subgroup showed promise, the overall topline results disappointed investors, triggering a significant selloff.
Latest ALMS news
- Alumis chief legal officer Sanam Pangali sells $2,164 in stock By Investing.com - Investing.com India · Investing.com India
- Form 4 Alumis Inc: Sanam Pangali (CLO) For: 2 November By Investing.com - Investing.com UK · Investing.com UK
FAQ
What is the current sentiment for ALMS stock?
Aggregate finance-aware sentiment across the last 2 indexed ALMS news stories is neutral (+0.00 on a -1 to +1 scale).
Why did ALMS stock move recently?
ALMS last moved -56.58% (negative). ALMS experienced a sharp 56.6% decline primarily due to its Phase 2b LUMUS trial for envudeucitinib in systemic lupus erythematosus (SLE) failing to meet primary and key secondary endpoints. Although a high-interferon subgroup showed promise, the overall topline results disappointed investors, triggering a significant selloff.